drugset / Trial / NCT00162448

A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators

NCT00162448 ↗

Phase 1 Completed 36 enrolled Bristol-Myers Squibb
RandomizedParallel-groupDouble-blindDiagnostic

Summary

Double-Blind, Randomized, Single-Dose Study to Evaluate the Atrial Selectivity and Safety of BMS-394136 in Subjects with Implanted Dual-Chamber Pacemakers or Defibrillators

Timeline

Start
2005-01
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-394136 Small molecule 100 mg Oral

Indications